Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

Cited by (1,000)

Items 401–500 of 1,000

1. The Inflammatory Form of Cerebral Amyloid Angiopathy or “Cerebral Amyloid Angiopathy-Related Inflammation” (CAARI)
   Howard S. Kirshner, Michael Bradshaw · 2015 · Current Neurology and Neuroscience Reports
2. Characterization of a double (amyloid precursor protein-tau) transgenic: Tau phosphorylation and aggregation
   Mar Pérez, Elena M. Ribé, Alicia Rubio, Filip Lim, M.A. Morán, Pilar Gómez‐Ramos, Isidró Ferrer, M.T.G. Isla, Jesús Ávila · 2004 · Neuroscience
3. Current Treatment and Recent Clinical Research in Alzheimer's Disease
   Judith A. Neugroschl, Mary Sano · 2010 · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine
4. Reduced levels of Aβ 40 and Aβ 42 in brains of smoking controls and Alzheimer's patients
   Ewa Hellström‐Lindahl, Malahat T. Mousavi, R. Ravid, Agneta K. Nordberg · 2004 · Neurobiology of Disease
5. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine
   Cynthia Ann Lemere · 2009 · Progress in brain research
6. Immunological Aetiology of Major Psychiatric Disorders
   Barbara Sperner‐Unterweger · 2005 · Drugs
7. Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer’s disease
   Tsuyoshi Hamaguchi, Kenjiro Ono, Masahito Yamada · 2006 · Cellular and Molecular Life Sciences
8. Insulin rescues amyloid β-induced impairment of hippocampal long-term potentiation
   Lee, Cheng-Che, Kuo, Yu-Min, Huang, Chiung-Chun, Hsu, Kuei-Sen · 2009 · Neurobiology of Aging
9. Autoantibody-catalyzed Hydrolysis of Amyloid β Peptide
   Hiroaki Taguchi, Stephanie A. Planque, Yasuhiro Nishiyama, Jindrich Symersky, Stéphane Boivin, Paul Szabo, Robert Paul Friedland, Paul A. Ramsland, Allen B. Edmundson, Marc E. Weksler et al. · 2007 · Journal of Biological Chemistry
10. High mobility group box protein‐1 inhibits microglial Aβ clearance and enhances Aβ neurotoxicity
    Kazuyuki Takata, Yoshihisa Kitamura, Daiju Tsuchiya, Toshiyuki Kawasaki, Takashi Taniguchi, Shun Shimohama · 2004 · Journal of Neuroscience Research
11. Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders
    Kristi M. Anderson, Katherine E. Olson, Katherine A. Estes, Ken Flanagan, Howard Eliot Gendelman, Rodney Lee Mosley · 2014 · Translational Neurodegeneration
12. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Aβ antibody response with Alum to Quil A adjuvant switch
    Anahit Ghochikyan, Mikayel Mkrtichyan, Irina Petrushina, Nina Movsesyan, Adrine Karapetyan, David H. Cribbs, Michael G. Agadjanyan · 2005 · Vaccine
13. Alzheimer Disease
    Caselli, Richard J., Beach, Thomas G., Knopman, David S., Graff-Radford, Neill R. · 2017 · Mayo Clinic Proceedings
14. Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer’s disease mice
    Kiyota, Tomomi, Machhi, Jatin, Lu, Yaman, Dyavarshetty, Bhagyalaxmi, Nemati, Maryam, Yokoyama, Izumi, Mosley, R.L., Gendelman, Howard E. · 2018 · Journal of Neuroimmunology
15. Potential Therapeutic Strategies for Alzheimer’s Disease Targeting or Beyondβ-Amyloid: Insights from Clinical Trials
    Qiutian Jia, Yulin Deng, Hong Qing · 2014 · BioMed Research International
16. Murine models of Alzheimer's disease and their use in developing immunotherapies
    Thomas Wısnıewskı, Einar M. Sigurdsson · 2010 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
17. Amyloid-β specific regulatory T cells attenuate Alzheimer’s disease pathobiology in APP/PS1 mice
    Pravin Yeapuri, Jatin Machhi, Yaman Lu, Mai Mohamed Abdelmoaty, Rana Kadry, Milankumar Patel, Shaurav Bhattarai, Eugene Lu, Krista L. Namminga, Katherine E. Olson et al. · 2023 · Molecular Neurodegeneration
18. A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection
    Yumiko Ishii, 中江智子, Fumiko Sakamoto, Kazuhiko Matsuo, Keisuke Matsuo, Ying‐Shu Quan, Fumio Kamiyama, Takuya Fujita, Akira Yamamoto, Shinsaku Nakagawa et al. · 2008 · Journal of Controlled Release
19. Kinetics of Cerebral Amyloid Angiopathy Progression in a Transgenic Mouse Model of Alzheimer Disease
    Elissa M. Robbins, Rebecca A. Betensky, Sarah B. Domnitz, Susan M. Purcell, Mónica Garcı́a-Alloza, Charles Greenberg, George William Rebeck, Bradley T. Hyman, Steven Mark Greenberg, Matthew P. Frosch et al. · 2006 · Journal of Neuroscience
20. Microglial cells in neurodegenerative disorders.
    Marcin Wojtera, Beata Sikorska, Tomasz Sobów, Pawel Piotr Liberski · 2005 · PubMed
21. Protective and Regenerative Roles of T Cells in Central Nervous System Disorders
    Frances Evans, Marie Dittmer, Alerie Guzman de la Fuente, Denise C. Fitzgerald · 2019 · Frontiers in Immunology
22. Current Therapeutic Options for Alzheimers Disease
    Alberto Lleó · 2007 · Current Genomics
23. Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ levels
    Nienke Timmer, Laura van Dijk, Catharina E.E.M. Van der Zee, Amanda J. Kiliaan, Robert M.W. de Waal, Marcel M. Verbeek · 2010 · Neurobiology of Disease
24. IL-1β-driven amyloid plaque clearance is associated with an expansion of transcriptionally reprogrammed microglia
    Rivera-Escalera, Fátima, Pinney, Jonathan J., Owlett, Laura, Ahmed, Hoda, Thakar, Juilee, Olschowka, John A., Elliott, Michael R., O’Banion, M. Kerry · 2019 · Journal of Neuroinflammation
25. Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: Maintenance of brain iron homeostasis
    Sanghamitra Bandyopadhyay, Jack T. Rogers · 2014 · Biochemical Pharmacology
26. Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy
    Seth Love · 2009 · Frontiers in bioscience
27. Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease
    Susann Cattepoel, Michael Hanenberg, Luka Kulic, Roger M. Nitsch · 2011 · PLoS ONE
28. In vitro models and systems for evaluating the dynamics of drug delivery to the healthy and diseased brain
    Hassan Pezeshgi Modarres, Mohsen Janmaleki, Mana Novin, John Saliba, Fatima El Hajj Moussa, Mahdi Rezayati Charan, Amir Seyfoori, Hamid SadAbadi, Milène Vandal, Minh Dang Nguyen et al. · 2018 · Journal of Controlled Release
29. Beyond the Signal Sequence: Protein Routing in Health and Disease
    Cecilia Castro-Fernández, Guadalupe Maya‐Núñez, P. Michael Conn · 2004 · Endocrine Reviews
30. Aβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy
    Sakai, Kenji, Boche, Delphine, Carare, Roxana, Johnston, David, Holmes, Clive, Love, Seth, Nicoll, James A. R. · 2014 · Acta Neuropathologica
31. Three major effects of APOEε4 on Aβ immunotherapy induced ARIA
    Kate E. Foley, Donna M. Wilcock · 2024 · Frontiers in Aging Neuroscience
32. Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy
    Vitaly Vasilevko, Giselle Fazzioni Passos, Daniel Quiring, Elizabeth Head, Richard C. Kim, Mark Fisher, David H. Cribbs · 2010 · Annals of the New York Academy of Sciences
33. Virus‐based nanoparticles as platform technologies for modern vaccines
    Karin L. Lee, Richard M. Twyman, Steven Fiering, Nicole F. Steinmetz · 2016 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
34. The role of the immune system in driving neuroinflammation
    Ní Chasaide, Caitlín, Lynch, Marina A · 2020 · Brain and Neuroscience Advances
35. Apolipoprotein C-III is an Amyloid-β-Binding Protein and an Early Marker for Alzheimer's Disease
    Yao‐Hsiang Shih, Kuen‐Jer Tsai, Chu-Wan Lee, Shu‐Chu Shiesh, Wei-Ting Chen, Ming‐Chyi Pai, Yu‐Min Kuo · 2014 · Journal of Alzheimer s Disease
36. CD 4 T cells in immunity and immunotherapy of A lzheimer's disease
    Alon Monsonego, Anna Nemirovsky, Idan Harpaz · 2013 · Immunology
37. Aβ-directed Single-chain Antibody Delivery Via a Serotype-1 AAV Vector Improves Learning Behavior and Pathology in Alzheimer's Disease Mice
    Deborah A. Ryan, Michael A. Mastrangelo, Wade C. Narrow, Mark A. Sullivan, Howard J. Federoff, William J. Bowers · 2010 · Molecular Therapy
38. In the Footsteps of Alchemists
    Christopher Martin Dobson · 2004 · Science
39. Decreased serum amyloid β1–42 autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1–42 peptide
    Sylvia Brettschneider, Nils G. Morgenthaler, Stefan Johannes Teipel, Christina Fischer-Schulz, Katharina Bürger, Richard C. Dodel, Yansheng Du, Hans‐Jürgen Möller, Andreas Bergmann, Harald Juergen Hampel · 2005 · Biological Psychiatry
40. Biomarkers for early diagnosis of Alzheimer disease: ‘ALZheimer ASsociated gene’– a new blood biomarker?
    K. A. Jellinger, Bernd Janetzky, Johannes Attems, Elisabeth Kienzl · 2008 · Journal of Cellular and Molecular Medicine
41. Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases
    Irena Kadiu, Jason G. Glanzer, Jonathan Kipnis, Howard Eliot Gendelman, MARK P. THOMAS · 2005 · Neurotoxicity Research
42. Conformation-sensitive Antibodies against Alzheimer Amyloid-β by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide
    Nadia Moretto, Angelo Bolchi, Claudio Rivetti, Bruno Pietro Imbimbo, Gino Villetti, Vladimiro Pietrini, Luciano Polonelli, Steven J. Del Signore, Karen M. Smith, Robert J. Ferrante et al. · 2007 · Journal of Biological Chemistry
43. Absence of β-Amyloid Deposits After Immunization in Alzheimer Disease With Lewy Body Dementia
    Stéphanie Bombois, Claude‐Alain Maurage, Marie Gompel, Vincent Deramecourt, Marie‐Anne Mackowiak‐Cordoliani, Ronald S. Black, Rodolphe Lavielle, André Delacourte, Florence Pasquier · 2007 · Archives of Neurology
44. Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
    Ross Penninkilampi, Holly M. Brothers, Guy D. Eslick · 2016 · Journal of Neuroimmune Pharmacology
45. Royal Jelly Alleviates Cognitive Deficits and β-Amyloid Accumulation in APP/PS1 Mouse Model Via Activation of the cAMP/PKA/CREB/BDNF Pathway and Inhibition of Neuronal Apoptosis
    Mengmeng You, Yongming Pan, Yichen Liu, Yifan Chen, Yuqi Wu, Juan‐Juan Si, Kai Wang, Fuliang Hu · 2019 · Frontiers in Aging Neuroscience
46. Early minor stimulation of microglial TLR2 and TLR4 receptors attenuates Alzheimer's disease–related cognitive deficit in rats: behavioral, molecular, and electrophysiological evidence
    Pourbadie, Hamid Gholami, Sayyah, Mohammad, Khoshkholgh-Sima, Baharak, Choopani, Samira, Nategh, Mohsen, Motamedi, Fereshteh, Shokrgozar, Mohammad Ali · 2018 · Neurobiology of Aging
47. Degradation of amyloid beta by human induced pluripotent stem cell-derived macrophages expressing Neprilysin-2
    Koutaro Takamatsu, Tokunori Ikeda, Miwa Haruta, Keiko Matsumura, Yasuhiro Ogi, Naomi Nakagata, Makoto Uchino, Yukio Ando, Yasuharu Nishimura, Satoru Senju · 2014 · Stem Cell Research
48. Non human primate models for Alzheimer’s disease-related research and drug discovery
    Debby Van Dam, Peter Paul De Deyn · 2016 · Expert Opinion on Drug Discovery
49. Nanomedicine-based immunotherapy for central nervous system disorders
    Sumaira Hanif, Pir Muhammad, Rose Chesworth, Fawad Ur Rehman, Rongjun Qian, Meng Zheng, Bingyang Shi · 2020 · Acta Pharmacologica Sinica
50. Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer’s Disease Immunotherapy
    Jing Liu, Bin Yang, Jun Ke, Wenjia Li, Wen-Chen Suen · 2016 · Drugs & Aging
51. Amyloid-Beta Immunotherapy for the Prevention and Treatment of Alzheimer Disease: Lessons from Mice, Monkeys, and Humans
    Cynthia Ann Lemere, Marcel Maier, Liying Jiang, Ying Peng, Timothy J. Seabrook · 2006 · Rejuvenation Research
52. Animal models of dementia
    Erik D. Roberson, Aimee W. Kao · 2009 · Cambridge University Press eBooks
53. Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse
    Peter A. Seubert, Robin Barbour, Karen Khan, Ruth N. Motter, Pearl Tang, Dora Kholodenko, Kristin Kling, Dale Schenk, Kelly Johnson‐Wood, Sally Schroeter et al. · 2008 · Neurodegenerative Diseases
54. Alzheimer's disease and blood–brain barrier function—Why have anti-β-amyloid therapies failed to prevent dementia progression?
    Jens Pahnke, Lary C. Walker, Katja Scheffler, Markus Krohn · 2009 · Neuroscience & Biobehavioral Reviews
55. A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease
    Michael G. Agadjanyan, Nikolai Petrovsky, Anahit Ghochikyan · 2015 · Alzheimer s & Dementia
56. Nonviral Aβ DNA vaccine therapy against Alzheimer’s disease: Long-term effects and safety
    Yoshio Okura, Akira Miyakoshi, Kuniko Kohyama, Il-Kwon Park, Matthias Staufenbiel, Yoh Matsumoto · 2006 · Proceedings of the National Academy of Sciences
57. Aβ Immunotherapy Protects Morphology and Survival of Adult-Born Neurons in Doubly Transgenic APP/PS1 Mice
    Barbara Biscaro, Olle Lindvall, Christoph Höck, Christine T. Ekdahl, Roger M. Nitsch · 2009 · Journal of Neuroscience
58. How to Get from Here to There: Macrophage Recruitment in Alzheimers Disease
    Kavon P. Rezai-Zadeh, David Gate, Genevíève Gowing, Terrence Town · 2011 · Current Alzheimer Research
59. Th1 Polarization of T Cells Injected into the Cerebrospinal Fluid Induces Brain Immunosurveillance
    Yair Fisher, Itai Strominger, Shva Biton, Anna Nemirovsky, Rona Baron, Alon Monsonego · 2013 · The Journal of Immunology
60. A Selective Prostaglandin E2 Receptor Subtype 2 (EP2) Antagonist Increases the Macrophage-Mediated Clearance of Amyloid-Beta Plaques
    Brian M. Fox, Hilary P. Beck, Philip M. Roveto, Frank Kayser, Qingwen Cheng, Hannah Dou, Toni L. Williamson, James J. S. Treanor, Hantao Liu, Lixia Jin et al. · 2015 · Journal of Medicinal Chemistry
61. Immune Regulation of Antibody Access to Neuronal Tissues
    Akiko Iwasaki · 2017 · Trends in Molecular Medicine
62. An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice
    Jeffrey L. Frost, Bin Liu, Jens‐Ulrich Rahfeld, Martin Kleinschmidt, Brian O’Nuallain, Kevin X. Le, Inge Lues, Barbara J. Caldarone, Stephan Schilling, Hans‐Ulrich Demuth et al. · 2015 · Neurobiology of Aging
63. Transcutaneous β-amyloid immunization reduces cerebral β-amyloid deposits without T cell infiltration and microhemorrhage
    William V. Nikolic, Yun Bai, Demian F. Obregon, Huayan Hou, Takashi Mori, Jin Zeng, Jared C. Ehrhart, R. Douglas Shytle, Brian N. Giunta, David Morgan et al. · 2007 · Proceedings of the National Academy of Sciences
64. Neutralization of Soluble, Synaptotoxic Amyloid β Species by Antibodies Is Epitope Specific
    Zago, Wagner, Buttini, Manuel, Comery, Thomas A., Nishioka, Christopher, Gardai, Shyra J., Seubert, Peter, Games, Dora, Bard, Frédérique, Schenk, Dale, Kinney, Gene G. · 2012 · The Journal of Neuroscience
65. Immune mechanisms and shared immune targets in neurodegenerative diseases
    Howard L. Weiner · 2024 · Nature Reviews Neurology
66. Extracellular tau induces microglial phagocytosis of living neurons in cell cultures
    Katryna Pampuščenko, Ramunė Morkūnienė, Tomas Šneideris, Vytautas Smirnovas, Rima Budvytytė, Gintaras Valinčius, Guy Charles Brown, Vilmantė Borutaitė · 2019 · Journal of Neurochemistry
67. Targeting β-Amyloid Pathology in Alzheimer's Disease with Aβ Immunotherapy
    Roger M. Nitsch, Christoph Höck · 2008 · Neurotherapeutics
68. Metal-protein attenuating compounds and Alzheimer’s disease
    Craig William Ritchie, Ashley Ian Bush, Colin Louis Masters · 2004 · Expert Opinion on Investigational Drugs
69. Breaking Immune Tolerance to the Prion Protein Using Prion Protein Peptides Plus Oligodeoxynucleotide-CpG in Mice
    M. Bruley-Rosset, Clara Ballerini, Sylvie Grégoire, Pat Metharom, Claude Carnaud, Pièrre Aucouturier · 2004 · The Journal of Immunology
70. Inflammation and Microglia Actions in Alzheimer’s Disease
    Colin Kelly Combs · 2009 · Journal of Neuroimmune Pharmacology
71. Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?
    Frédéric Checler, Elissa Afram, Raphaëlle Pardossi‐Piquard, Inger Lauritzen · 2021 · Journal of Biological Chemistry
72. Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice
    Chang‐Hyun Song, Hidefumi Furuoka, Chan-Lan Kim, Michiko Ogino, Akio Suzuki, Rie Hasebe, Motohiro Horiuchi · 2008 · Journal of General Virology
73. Aβ Immunotherapy: Lessons Learned for Potential Treatment of Alzheimer’s Disease
    Dale B. Schenk, Peter A. Seubert, Michael Grundman, Ron Black · 2005 · Neurodegenerative Diseases
74. An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion
    Frederik Barkhof, Marita Daams, Philip Scheltens, H. Robert Brashear, Henry Michael Arrighi, Arianne Bechten, Kristen Morris, M. McGovern, Mike Peter Wattjes · 2013 · American Journal of Neuroradiology
75. Dementia Update 2005
    John C. Morris · 2005 · Alzheimer Disease & Associated Disorders
76. Alzheimer disease neuropathology in a patient previously treated with aducanumab
    Edward D. Plowey, Thierry Bussière, Raj Rajagovindan, Jennifer Sebalusky, Stefan Hamann, Christian von Hehn, Carmen Castrillo‐Viguera, Alfred W. Sandrock, Samantha Budd Haeberlein, Christopher H. van Dyck et al. · 2022 · Acta Neuropathologica
77. Immunization Therapy for Alzheimer Disease: A Comprehensive Review of Active Immunization Strategies
    Takeshi Tabira · 2010 · The Tohoku Journal of Experimental Medicine
78. What does complement do in Alzheimer’s disease? Old molecules with new insights
    Yong Shen, Libang Yang, Rena Li · 2013 · Translational Neurodegeneration
79. New treatment strategies for Alzheimer's disease: is there a hope?
    Iván Aprahamian, Florindo Stella, Orestes Vicente Forlenza · 2013 · Europe PMC (PubMed Central)
80. The immune system, amyloid‐β peptide, and Alzheimer's disease
    Marc E. Weksler, Gunnar K. Gouras, Norman R. Relkin, Paul Szabo · 2005 · Immunological Reviews
81. Antibody‐based approaches in Alzheimer’s research: safety, pharmacokinetics, metabolism, and analytical tools
    Peter Lichtlen, M. Hasan Mohajeri · 2007 · Journal of Neurochemistry
82. Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab
    Lukas Sveikata, Andreas Charidimou, Anand Viswanathan · 2021 · Stroke
83. Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles.
    Spohn, Gunther, Schwarz, Katrin, Maurer, Patrik, Illges, Harald, Rajasekaran, Narendiran, Choi, Yongwon, Jennings, Gary T, Bachmann, Martin F · 2005 · The Journal of Immunology
84. Correlation between astrocyte apoptosis and Alzheimer changes in gray matter lesions in Alzheimer's disease
    Kobayashi, Katsuji, Hayashi, Masahiro, Nakano, Hiroyuki, Shimazaki, Masao, Sugimori, Kaoru, Koshino, Yoshifumi · 2005 · Journal of Alzheimer s Disease
85. Small molecule inhibitors of Abetaassembly
    Harry LeVine · 2007 · Amyloid
86. Loss of P2Y2 Nucleotide Receptors Enhances Early Pathology in the TgCRND8 Mouse Model of Alzheimer's Disease
    Deepa Ajit, Lucas T. Woods, Jean M. Camden, Christina N. Thebeau, Farid G. El-Sayed, Glen W. Greeson, Laurie Erb, Michael J. Petris, Douglas C. Miller, Grace Y. Sun et al. · 2013 · Molecular Neurobiology
87. Neurochemical dementia diagnostics: State of the art and research perspectives
    Piotr Lewczuk, Jens Wiltfang · 2008 · PROTEOMICS
88. Microglial Amyloid- β 1-40 Phagocytosis Dysfunction Is Caused by High-Mobility Group Box Protein-1: Implications for the Pathological Progression of Alzheimer’s Disease
    Kazuyuki Takata, Tetsuya Takada, Aina Ito, Mayo Asai, Manami Tawa, Yuki Saito, Eishi Ashihara, Hidekazu Tomimoto, Yoshihisa Kitamura, Shun Shimohama · 2012 · International Journal of Alzheimer s Disease
89. p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice
    Ken C. Walls, Rahasson R. Ager, Vitaly Vasilevko, Dave Cheng, Rodrigo Medeiros, Frank M. LaFerla · 2014 · Neuroscience Letters
90. Antibody-based therapy in Alzheimer's disease
    Refik Pul, Richard C. Dodel, Martin Stangel · 2011 · Expert Opinion on Biological Therapy
91. Developing therapeutic vaccines against Alzheimer’s disease
    Thomas Wısnıewskı, Eleanor Drummond · 2015 · Expert Review of Vaccines
92. Membrane-Accelerated Amyloid-β Aggregation and Formation of Cross-β Sheets
    Adree Khondker, Richard J. Alsop, Maikel Christian Rheinstadter · 2017 · Membranes
93. Review: Neuropathology and behavioural features of transgenic murine models of Alzheimer's disease
    Kamar E. Ameen‐Ali, Stephen B. Wharton, Julie E. Simpson, Paul Roy Heath, Paul S. Sharp, Jason Berwick · 2017 · Neuropathology and Applied Neurobiology
94. Quantitative analysis of amyloid plaques in a mouse model of Alzheimer’s disease by phase-contrast X-ray computed tomography
    Kyoko Noda-Saita, Akio Yoneyama, Yoshitsugu Shitaka, Yasuharu Hirai, Kazuhiro Terai, J. Wu, Tetsuro Takeda, Kazuyuki Hyodo, Nobuyuki Osakabe, T. Yamaguchi et al. · 2006 · Neuroscience
95. AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy
    Ising, Christina, Gallardo, Gilbert, Leyns, Cheryl E.G., Wong, Connie H., Jiang, Hong, Stewart, Floy, Koscal, Lauren J., Roh, Joseph, Robinson, Grace O., Remolina Serrano, Javier et al. · 2017 · Journal of Experimental Medicine
96. T Cell-Mediated Autoimmunity in Glaucoma Neurodegeneration
    Lixiang Wang, Xin Wei · 2021 · Frontiers in Immunology
97. Early intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of Alzheimer disease
    Lydia Giménez‐Llort, Geovanny Rivera-Hernández, Marta Marin‐Argany, José Luis Sánchez‐Quesada, Sandra Villegas · 2013 · mAbs
98. Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target
    Sebastian Scott Oakley, Mahmoud Bukar Maina, Karen E. Marshall, Youssra K. Al‐Hilaly, Charlie Harrington, Claude M. Wischik, Louise C. Serpell · 2020 · Frontiers in Neurology
99. Cerebral beta-amyloid angiopathy in aged squirrel monkeys.
    Hanie A. Elfenbein, Rebecca F. Rosen, S L Stephens, R.C. Switzer, Yoland Smith, Jean‐François Paré, Pankaj D Mehta, R Warzok, Lary C. Walker · 2007 · PubMed
100. Emerging prospects for the disease-modifying treatment of Alzheimer's disease
     Lary C. Walker, Chris Ibegbu, Charles W. Todd, Harriet L. Robinson, Mathias Jucker, Harry LeVine, Sam Gandy · 2005 · Biochemical Pharmacology